Clinical evaluation of plasma insulin and C-peptide levels with 3 different high-flux dialyzers in diabetic patients on hemodialysis.
OBJECTIVE
Changes in plasma immunoreactive insulin (IRI) and connecting-peptide immunoreactivity (CPR) concentrations during hemodialysis (HD) were evaluated in diabetic HD patients with 3 different high-flux membranes. The removal properties of the membranes were compared.


METHODS
In this prospective controlled study, 15 stable diabetic patients on HD were randomly selected for 6 HD sessions with 3 different membranes: polysulfone (PS), cellulose triacetate (CTA), and polymethylmethacrylate (PMMA). Blood samples were obtained from the blood tubing at the arterial (A) site at the beginning and end of the sixth HD session. At 60 minutes after dialysis initiation, blood samples were obtained from both the A and venous (V) sites of the dialyzer to investigate the clearance and removal properties of the membranes.


RESULTS
The plasma IRI and CPR levels decreased significantly at each time point with all 3 membranes. IRI clearance with the PS membrane was significantly higher than that with the CTA and PMMA membranes. No difference was observed in the IRI reduction rate between the 3 membranes. CPR clearance and reduction rate with the PMMA membrane were lower than with the PS and CTA membranes. No significant difference was observed in serum creatinine clearance and reduction rates between the 3 membranes; however, serum urea nitrogen clearance was significantly lower with the PMMA membrane compared with the PS and CTA membranes. A significantly high beta2-microglobulin clearance and reduction rate was achieved in the order PS > CTA > PMMA.


CONCLUSIONS
Plasma IRI and CPR are cleared by HD; their clearance rates differ with the dialyzer membranes. Plasma IRI clearance with the PS membrane is higher than that with the CTA and PMMA membranes.
Abe
M
M
Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University School of Medicine, Tokyo. mabe@med.nihon-u.ac.jp
Okada
K
K
Maruyama
T
T
Inoshita
A
A
Ikeda
K
K
Uto
E
E
Kikuchi
F
F
Matsumoto
K
K
D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood*; D002482:Cellulose / Q000031:analogs & derivatives; D003404:Creatinine / Q000097:blood; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications; D003928:Diabetic Nephropathies / Q000097:blood* / Q000628:therapy*; D004867:Equipment Design; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood*; D008567:Membranes, Artificial; D011108:Polymers; D019904:Polymethyl Methacrylate; D006435:Renal Dialysis / Q000295:instrumentation* / Q000379:methods*; D012709:Serum Albumin / Q000378:metabolism; D013450:Sulfones; D014508:Urea / Q000097:blood; D014511:Uremia / Q000097:blood / Q000188:drug therapy
D001786:Blood Glucose; D002096:C-Peptide; D006454:Hemoglobins; D007328:Insulin; D008567:Membranes, Artificial; D011108:Polymers; D012709:Serum Albumin; D013450:Sulfones; C017662:polysulfone P 1700; D014508:Urea; D002482:Cellulose; D019904:Polymethyl Methacrylate; C024671:cellulose triacetate; D003404:Creatinine